SELLAS Life Sciences Group, Inc. 8-K

What Happened

• SELLAS Life Sciences Group, Inc. filed an 8-K reporting a preliminary, unaudited cash and cash equivalents balance of $138.3 million as of June 30, 2026. The company cautioned this amount is subject to closing procedures and management review and may change in the final financials.
• Separately, on July 24, 2026, the sole arbitrator in an HKIAC arbitration between SELLAS and 3D Medicines dismissed SELLAS’s claims. The arbitrator administratively allocated approximately $1.0 million of 3D Medicines’ legal fees and costs to SELLAS. 3D Medicines stated it will continue development and commercialization of galinpepimut‑S (GPS) in Greater China under the exclusive license.

Key Details

• Preliminary cash and cash equivalents: $138.3 million as of June 30, 2026 (unaudited, preliminary).
• Arbitration decision date: July 24, 2026 — SELLAS’s claims dismissed by the sole arbitrator.
• Allocated legal fees/costs to SELLAS: approximately $1.0 million.
• Licensed program milestone context: $191.5 million in potential future milestone payments remained under the exclusive license as of March 31, 2026, including $13.0 million in milestone payments that were part of the arbitration dispute.

Why It Matters

• Cash position: The preliminary $138.3M balance is a key indicator of SELLAS’s near‑term liquidity and ability to fund operations or programs; because it is unaudited and preliminary, investors should watch the company’s upcoming interim financial statements for final figures.
• Arbitration outcome: The dismissal and the ~$1.0M fee allocation are near‑term financial impacts and resolve a dispute that could have affected timing or receipt of certain milestone payments. 3D Medicines’ statement that it will continue GPS development under the license means the contractual relationship remains in effect and substantial potential milestone payments ($191.5M as of 3/31/26) are still reported as possible future consideration. Investors should monitor future filings for any changes to milestone expectations or cash impacts.